Business
Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer
CAMBRIDGE, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Svetlana Makhni as Chief Financial Officer (CFO). Ms. Makhni will oversee Prime Medicine’s financial operations and strategy, including investor relations, financial planning and analysis, and corporate development. “We are delighted to welcome Svetlana to Pri
About this update from Prime Medicine, Inc.
[{"type":"image","alt":"Prime Medicine, Inc.","displaySize":"","headline":null,"caption":"Prime Medicine, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/7c5397d80babf7cd71ba3f6a787c0b3f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/enElHSTFfbV03_VsbkbkVQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MA--/https://media.zenfs.com/en/globenewswire.com/7c5397d80babf7cd71ba3f6a787c0b3f","width":300,"height":100}},"lazy":false},{"type":"text","content":"CAMBRIDGE, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Svetlana Makhni as Chief Financial Officer (CFO). Ms. Makhni will oversee Prime Medicine’s financial operations and strategy, including investor relations, financial planning and analysis, and corporate development.","length":455,"tagName":"p"},{"type":"text","content":"“We are delighted to welcome Svetlana to Prime Medicine,” said Allan Reine, M.D., Chief Executive Officer of Prime Medicine. “Svetlana brings proven leadership at clinical-stage biotechnology companies, as well as deep capital markets expertise. As we prepare to enter the clinic in both Wilson Disease and Alpha-1 Antitrypsin Deficiency, her leadership will be instrumental in ensuring Prime Medicine is well positioned - both financially and strategically - to execute on the tremendous promise of Prime Editing for patients with Wilson Disease, AATD and beyond.”","length":565,"tagName":"p"},{"type":"text","content":"Ms. Makhni brings over 20 years of experience across multiple biotechnology and healthcare CFO and investment banking roles. Prior to joining Prime Medicine, she served as CFO of Marengo Therapeutics, a clinical-stage immuno-oncology company, where she led all aspects of the finance organization, including business development, investor relations and corporate development. In this role, Ms. Makhni played a key role in the execution of multiple high-value strategic partnerships, including transactions with Ipsen and Gilead Sciences. Previously, Ms. Makhni served as CFO of Escient Pharmaceuticals and CFO and Head of Operations at Bierman ABA.","length":648,"tagName":"p"},{"type":"text","content":"Earlier in...